Many failed clinical trials for Alzheimer’s disease therapies, Charlotte Shubert writes, focused on peptide amyloid-beta, which forms clumps in the brain. Charlotte reports in the Journal Club section of the Proceedings of the National Academy of Sciences that because of these failures, researchers are going back to the bench. They’re taking a closer look at other amyloid peptides—what they do and if they could they be a key to understanding Alzheimer’s. @schubertcm and image: Nature, Drs. Rudolph Tanzi and Doo Yeon Kim